Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan

Author： Iseki Kunitoshi  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.4, 2008-03, pp. : 601-610

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis

By  

Hemodialysis International, Vol. 20, Iss. 4, 2016-10 ,pp. : 589-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy

By Eandi Mario  

PharmacoEconomics, Vol. 28, Iss. 11, 2010-11 ,pp. : 1041-1054

Adis International

Access to resources Recommend Favorite

Early treatment with cinacalcet is more cost effective than delayed treatment for patients with hyperparathyroidism secondary to renal failure

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 529, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease

By Cheng Steven   Coyne Daniel  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 617-621

Informa Healthcare

Access to resources Recommend Favorite

Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism

By Franceschini Nora   Joy Melanie S   Kshirsagar Abhijit  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1413-1421

Informa Healthcare

Access to resources Recommend Favorite